Search

Call for research proposals within the Scientific Excellence Work Package of the GoCART Coalition

Dear GoCART community,

With more than 5,000 CAR-T infusions registered in the EBMT Registry, EBMT and EHA are proud to announce the third call for research proposals within the Scientific Excellence Work Package of the GoCART Coalition.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

EHA-EBMT 2nd European CAR T Cell Meeting

Dates:             January 30 – February 1, 2020
Location:        Sitges (Barcelona), Spain
Chairs:            H Einsele, C Chabannon

The 2nd edition of this meeting is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).…

Read more

EHA-EBMT 3rd European CAR T-cell Meeting (Virtual)

Dates: February 4-6, 2021

Chairs: H Einsele (EHA) & C Chabannon (EBMT)

For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) jointly organized the European CAR T-cell Meeting; this year in…

Read more

Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA

In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.

Read more